The development of modern cardiovascular medicines increasingly relies on sophisticated heterocyclic chemistry and carefully designed pharmaceutical intermediates. Rather than being produced through a single reaction, many innovative small-molecule drugs require a sequence of highly controlled transformations in which each intermediate contributes a specific structural component to the final molecule.

Esaxerenone, also known as CS-3150, is a representative example of this approach. It is a selective, non-steroidal mineralocorticoid receptor antagonist and has been developed for cardiovascular applications, including the treatment of hypertension. The compound has the CAS No. 1632006-28-0 and the molecular formula C₂₂H₂₁F₃N₂O₄S.

One of the important structural building blocks associated with Esaxerenone synthesis is 1-(2-hydroxyethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid, CAS No. 1631030-72-2.

For pharmaceutical manufacturers and sourcing teams, understanding the identity and role of this intermediate is important when evaluating supply-chain reliability, process consistency, and long-term availability.

1. Why Esaxerenone Is an Important Pharmaceutical Target

Esaxerenone belongs to the class of mineralocorticoid receptor antagonists.

Unlike traditional steroidal mineralocorticoid receptor antagonists, Esaxerenone is a non-steroidal compound with a structurally distinct pyrrole-based framework. KEGG classifies Esaxerenone as a cardiovascular agent and aldosterone antagonist, with the mineralocorticoid receptor (NR3C2) identified as its target.

The compound is also known by several identifiers, including:

• · Esaxerenone 
• · CS-3150 
• · XL-550 
• · CAS No. 1632006-28-0 

The FDA Substance Registration System identifies Esaxerenone under CAS 1632006-28-0 and provides its systematic chemical identity.

The development and commercialization of this type of targeted cardiovascular therapy create demand for reliable pharmaceutical intermediates capable of supporting reproducible multi-step synthesis.

2. The Key Pyrrole Intermediate

The SHLZ Pharma product is:

1-(2-Hydroxyethyl)-4-Methyl-5-(2-(Trifluoromethyl)phenyl)-1H-Pyrrole-3-Carboxylic Acid

CAS No.: 1631030-72-2

Molecular Formula: C₁₅H₁₄F₃NO₃

Molecular Weight: 313.27 g/mol

PubChem lists CAS 1631030-72-2 as a synonym for this compound and reports the molecular formula C₁₅H₁₄F₃NO₃ with a molecular weight of 313.27 g/mol. It also associates the compound with the name (5S)-1-(2-hydroxyethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid.

This distinction is important because the compound contains several structural features that are subsequently retained or transformed during pharmaceutical synthesis.

3. What Makes This Intermediate Chemically Valuable?

The value of this intermediate comes from the combination of several functional groups within one molecular framework.

Pyrrole Ring

The pyrrole ring forms the central heterocyclic framework and provides a versatile platform for subsequent functionalization.

Trifluoromethylphenyl Group

The trifluoromethyl (CF₃) substituent is an important structural feature in medicinal chemistry.

Fluorinated groups are frequently incorporated into pharmaceutical molecules because they can influence:

• · Lipophilicity
• · Metabolic stability
• · Molecular interactions
• · Electronic properties
• · Overall pharmacokinetic behavior

Hydroxyethyl Group

The 2-hydroxyethyl substituent provides an additional functional handle and contributes to the molecular architecture found in Esaxerenone.

Carboxylic Acid Function

The carboxylic acid group provides a highly useful synthetic handle for subsequent transformations, particularly in the preparation of more advanced amide-containing pharmaceutical structures.

Together, these groups make the compound more than simply a basic pyrrole derivative—it is a highly functionalized intermediate designed for further synthetic development.

4. From Carboxylic Acid to the Esaxerenone Framework

A useful way to understand this intermediate is to examine the structural relationship between the intermediate and the final drug.

The supplied intermediate contains:

1-(2-hydroxyethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid

Esaxerenone contains a closely related pyrrole framework, but its carboxylic acid functionality is converted into an amide containing a 4-(methylsulfonyl)phenyl group.

The final Esaxerenone structure is:

1-(2-hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide

This structural relationship can be verified through the FDA substance record and commercial reference-standard databases.

Therefore, the product should be positioned accurately as a pharmaceutical intermediate associated with Esaxerenone synthesis, rather than being described as Esaxerenone itself.

This distinction is especially important for pharmaceutical B2B marketing because technical buyers generally expect precise chemical descriptions.

5. The Importance of the (5S) Intermediate

One of the keywords associated with this product is:

(5S)-1-(2-hydroxyethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid

Stereochemistry can become particularly important in pharmaceutical manufacturing because different stereoisomers may exhibit different biological, physical, or synthetic characteristics.

PubChem lists the (5S) name among the synonyms associated with CAS 1631030-72-2.

For pharmaceutical manufacturers, therefore, control of:

• · Chemical purity
• · Stereochemical identity
• · Impurity profile
• · Batch consistency
• · Analytical characterization

can be critical when an intermediate is incorporated into a multi-step synthesis.

This creates a clear opportunity for specialized manufacturers with strong process-control capabilities.

6. Related Upstream Building Block

Another relevant keyword for this product is:

1H-Pyrrole-3-carboxylic acid, 4-methyl-5-[2-(trifluoromethyl)phenyl]-, ethyl ester

This compound represents an ethyl ester form of the corresponding pyrrole-3-carboxylic acid framework.

From a process-development perspective, ester and acid forms can serve different purposes depending on the synthetic route. Transformation between these functional groups provides chemists with flexibility when designing scalable reaction sequences.

This also illustrates why pharmaceutical intermediate sourcing should not focus only on a single CAS number.

A reliable supplier should understand the relationship between upstream building blocks, advanced intermediates, and downstream pharmaceutical targets.

7. Why Demand for Esaxerenone Intermediates Matters

The pharmaceutical intermediate market is increasingly moving toward specialized molecules rather than simple commodity chemicals.

Esaxerenone-related intermediates demonstrate several characteristics of this market:

Specialized Molecular Structures

The combination of fluorine, heterocyclic chemistry, stereochemistry, and multiple functional groups creates a higher technical barrier to manufacturing.

Multi-Step Pharmaceutical Synthesis

Advanced APIs typically require several synthetic stages, meaning that upstream intermediate quality can have a significant impact on downstream production.

Increasing Outsourcing

Pharmaceutical companies and CDMOs frequently outsource the manufacture of specialized intermediates to experienced chemical manufacturers.

Long-Term Supply Requirements

Once an intermediate becomes part of an established manufacturing route, customers often require stable quality and reliable long-term supply rather than one-time laboratory quantities.

For manufacturers with strong process-development capabilities, these trends create opportunities to become long-term supply-chain partners rather than simple chemical vendors.

8. What Pharmaceutical Buyers Should Evaluate

When sourcing Esaxerenone intermediates, price is only one part of the decision.

Experienced pharmaceutical procurement teams typically need to evaluate several additional factors.

Chemical Consistency

Does the supplier maintain consistent purity from batch to batch?

Analytical Support

Can the supplier provide appropriate analytical documentation and characterization?

Manufacturing Scale

Can production move from laboratory quantities to larger commercial requirements?

Process Stability

Is the manufacturing route sufficiently optimized for repeatable production?

Supply Reliability

Can the supplier maintain consistent delivery schedules over the long term?

Technical Communication

Can the manufacturer communicate effectively with R&D, process chemistry, and procurement teams?

These considerations become increasingly important when intermediates are used in regulated pharmaceutical manufacturing.

9. SHLZ Pharma as a Pharmaceutical Intermediate Supplier

SHLZ Pharma focuses on the development and manufacture of pharmaceutical intermediates and specialty chemicals for international customers.

For products such as 1-(2-hydroxyethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid, our value proposition is centered on several areas.

Process Development

Our technical team focuses on optimizing reaction conditions and production processes to improve reproducibility and manufacturing efficiency.

Quality Control

Strict analytical procedures help monitor product purity, impurities, and batch consistency throughout production.

Flexible Production

Different pharmaceutical projects require different quantities. SHLZ Pharma can support customers from development-scale requirements through larger production programs.

Custom Synthesis

In addition to standard products, customized pharmaceutical intermediate development can be discussed according to customer specifications and project requirements.

International Supply

SHLZ Pharma serves overseas customers and provides professional communication, documentation, packaging, and logistics support for international pharmaceutical supply chains.

10. Frequently Asked Questions

What is CAS No. 1631030-72-2?

CAS No. 1631030-72-2 is associated with 1-(2-hydroxyethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid, with the molecular formula C₁₅H₁₄F₃NO₃ and molecular weight 313.27 g/mol.

Is 1631030-72-2 Esaxerenone?

No. 1631030-72-2 is an intermediate, while Esaxerenone has the CAS No. 1632006-28-0. The two compounds have closely related structural frameworks, but they are chemically distinct substances.

What is Esaxerenone used for?

Esaxerenone is a non-steroidal mineralocorticoid receptor antagonist and is classified as a cardiovascular/antihypertensive agent.

Why is the trifluoromethyl group important?

The CF₃ group is frequently used in medicinal chemistry because it can modify molecular electronic properties, lipophilicity, metabolic behavior, and molecular interactions.

Can SHLZ Pharma supply this intermediate for pharmaceutical projects?

SHLZ Pharma specializes in pharmaceutical intermediates and can discuss research, development, and larger-scale supply requirements with qualified customers.

Conclusion

The development of modern cardiovascular medicines depends on a reliable network of specialized pharmaceutical intermediates. 1-(2-Hydroxyethyl)-4-Methyl-5-(2-(Trifluoromethyl)phenyl)-1H-Pyrrole-3-Carboxylic Acid (CAS No. 1631030-72-2) represents an important functionalized pyrrole building block associated with synthetic routes toward Esaxerenone (CAS No. 1632006-28-0).

Its combination of a pyrrole ring, trifluoromethylphenyl group, hydroxyethyl substituent, and carboxylic acid functionality provides a valuable platform for further pharmaceutical synthesis. The relationship between this intermediate and the amide structure of Esaxerenone also demonstrates how carefully designed intermediates enable the construction of advanced pharmaceutical molecules.

For pharmaceutical companies, CDMOs, CROs, and sourcing organizations looking for a reliable Esaxerenone intermediate supplier, SHLZ Pharma provides specialized manufacturing capabilities, quality-focused production, flexible supply options, and international technical support.